Tech Company Financing Transactions
Dekkun Funding Round
On 9/30/2012, Dekkun announced $3.5 million in financing from HealthCare Ventures.
Transaction Overview
Company Name
Announced On
9/30/2012
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Pkwy. 102
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Not Recorded
Overview
DKN-01, which targets the Dickkopf-1 (DKK-1) protein, is an inhibitor of the canonical Wnt/ß-catenin signaling pathway. DKN-01 is presently being studied in Phase 1 clinical trials in tumors which have been linked to elevated circulating levels of DKK-1 or osteolytic bone disease, including non-small cell lung cancer and multiple myeloma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Medical Officer
Steven Landau
Browse more venture capital transactions:
Prev: 9/30/2012: Smart Furniture venture capital transaction
Next: 9/30/2012: Vital Access venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs